Recent Advancements in Treatment Approaches for NSCLC

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; Vice-President, Florida Society of Clinical Oncology, discusses key advancements made in treatment approaches for NSCLC in 2023.

EP. 1: Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC

January 12th 2024

Edgardo Santos, MD, FACP, FCCP, provides insights into the innovative Beamion Lung 1 trial, focused on assessing the safety and tolerability of zongertinib (BI 1810631) in patients with advanced, previously treated HER2+ non-small cell lung cancer (NSCLC).

EP. 2: Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials

January 12th 2024

Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.

EP. 3: Expert Perspectives on the Latest TROPION-Lung01 Data

January 19th 2024

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.

EP. 4: EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC

January 19th 2024

Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.

EP. 5: EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights

January 26th 2024

Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).

EP. 6: Future Perspectives on the Treatment of NSCLC

January 26th 2024

Dr Edgardo Santos highlights key takeaways from the presented data and provides insights into how these findings could shape the future landscape of healthcare directions.